Nephros Free Cash Flow 2010-2025 | NEPH
Nephros free cash flow from 2010 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Nephros Annual Free Cash Flow | |
|---|---|
| 2024 | -0.54 |
| 2023 | 0.75 |
| 2022 | -3.37 |
| 2021 | -1.45 |
| 2020 | -7.14 |
| 2019 | -2.29 |
| 2018 | -3.66 |
| 2017 | -0.08 |
| 2016 | -2.16 |
| 2015 | -3.83 |
| 2014 | -2.50 |
| 2013 | -3.58 |
| 2012 | -1.50 |
| 2011 | -1.30 |
| 2010 | -1.32 |
| 2009 | -2.64 |
| Nephros Quarterly Free Cash Flow | |
|---|---|
| 2025-06-30 | 1.32 |
| 2025-03-31 | 0.32 |
| 2024-12-31 | -0.54 |
| 2024-09-30 | -1.85 |
| 2024-06-30 | -1.22 |
| 2024-03-31 | -0.67 |
| 2023-12-31 | 0.75 |
| 2023-09-30 | 1.06 |
| 2023-06-30 | 0.50 |
| 2023-03-31 | 0.28 |
| 2022-12-31 | -3.37 |
| 2022-09-30 | -3.18 |
| 2022-06-30 | -3.01 |
| 2022-03-31 | -1.83 |
| 2021-12-31 | -1.45 |
| 2021-09-30 | -1.12 |
| 2021-06-30 | -0.20 |
| 2021-03-31 | -0.08 |
| 2020-12-31 | -7.14 |
| 2020-09-30 | -5.62 |
| 2020-06-30 | -3.79 |
| 2020-03-31 | -1.84 |
| 2019-12-31 | -2.29 |
| 2019-09-30 | -2.65 |
| 2019-06-30 | -2.03 |
| 2019-03-31 | -0.70 |
| 2018-12-31 | -3.66 |
| 2018-09-30 | -3.13 |
| 2018-06-30 | -2.01 |
| 2018-03-31 | -0.67 |
| 2017-12-31 | -0.08 |
| 2017-09-30 | -1.87 |
| 2017-06-30 | -1.16 |
| 2017-03-31 | -0.66 |
| 2016-12-31 | -2.16 |
| 2016-09-30 | -1.63 |
| 2016-06-30 | -0.83 |
| 2016-03-31 | -0.55 |
| 2015-12-31 | -3.83 |
| 2015-09-30 | -2.58 |
| 2015-06-30 | -1.45 |
| 2015-03-31 | -0.92 |
| 2014-12-31 | -2.50 |
| 2014-09-30 | -1.66 |
| 2014-06-30 | -0.87 |
| 2014-03-31 | -0.62 |
| 2013-12-31 | -3.58 |
| 2013-09-30 | -2.69 |
| 2013-06-30 | -2.56 |
| 2013-03-31 | -0.93 |
| 2012-12-31 | -1.50 |
| 2012-09-30 | -1.10 |
| 2012-06-30 | -0.38 |
| 2012-03-31 | 0.43 |
| 2011-12-31 | -1.29 |
| 2011-09-30 | -0.68 |
| 2011-06-30 | -1.09 |
| 2011-03-31 | -0.55 |
| 2010-12-31 | -1.32 |
| 2010-09-30 | -0.65 |
| 2010-06-30 | -0.71 |
| 2010-03-31 | -0.43 |
| 2009-12-31 | -2.63 |
| 2009-09-30 | |
| 2009-06-30 | |
| 2009-03-31 | -0.66 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.040B | $0.014B |
| Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.889B | 27.07 |
| Boston Scientific (BSX) | United States | $156.325B | 37.28 |
| Stryker (SYK) | United States | $149.639B | 30.46 |
| EssilorLuxottica (ESLOY) | France | $141.259B | 0.00 |
| Medtronic (MDT) | Ireland | $119.046B | 16.78 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.750B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.950B | 25.13 |
| ResMed (RMD) | United States | $40.192B | 28.74 |
| Agilent Technologies (A) | United States | $35.696B | 23.06 |
| GE HealthCare Technologies (GEHC) | United States | $33.662B | 15.82 |
| Terumo (TRUMY) | Japan | $26.606B | 31.53 |
| Koninklijke Philips (PHG) | Netherlands | $26.557B | 17.57 |
| Insulet (PODD) | United States | $23.925B | 80.16 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.018B | 13.38 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.402B | 0.00 |
| Baxter (BAX) | United States | $12.681B | 9.80 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.061B | 29.61 |
| Lantheus Holdings (LNTH) | United States | $3.733B | 10.09 |
| Envista Holdings (NVST) | United States | $3.520B | 24.63 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.349B | 14.86 |
| Perrigo (PRGO) | Ireland | $3.266B | 8.16 |
| ICU Medical (ICUI) | United States | $3.151B | 21.46 |
| Haemonetics (HAE) | United States | $2.628B | 11.73 |
| Acuren (TIC) | United States | $2.261B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $2.213B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.159B | 46.29 |
| QuidelOrtho (QDEL) | United States | $1.948B | 12.26 |
| Green Thumb Industries (GTBIF) | United States | $1.840B | 79.00 |
| AtriCure (ATRC) | United States | $1.838B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.519B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.503B | 17.74 |
| AdaptHealth (AHCO) | United States | $1.284B | 18.25 |
| Neogen (NEOG) | United States | $1.249B | 19.83 |
| BioLife Solutions (BLFS) | United States | $1.200B | 2505.00 |
| InMode (INMD) | Israel | $0.944B | 8.74 |
| Kestra Medical Technologies (KMTS) | United States | $0.829B | 0.00 |
| Valneva SE (VALN) | France | $0.753B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.740B | 0.00 |
| SNDL (SNDL) | Canada | $0.704B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.618B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.615B | 0.00 |
| ZimVie (ZIMV) | United States | $0.532B | 20.52 |
| Evolus (EOLS) | United States | $0.494B | 0.00 |
| Surmodics (SRDX) | United States | $0.487B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.479B | 16.50 |
| CeriBell (CBLL) | United States | $0.434B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.432B | 0.00 |
| Owens & Minor (OMI) | United States | $0.379B | 3.36 |
| Sanuwave Health (SNWV) | United States | $0.357B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.352B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.306B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.300B | 0.00 |
| Brainsway (BWAY) | Israel | $0.294B | 59.85 |
| High Tide (HITI) | Canada | $0.292B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.287B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.286B | 21.68 |
| Omeros (OMER) | United States | $0.283B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.260B | 0.00 |
| Cerus (CERS) | United States | $0.251B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.242B | 0.00 |
| Organigram Global (OGI) | Canada | $0.232B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.219B | 0.00 |
| Exagen (XGN) | United States | $0.217B | 0.00 |
| Quanterix (QTRX) | United States | $0.211B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.199B | 16.63 |
| FitLife Brands (FTLF) | United States | $0.175B | 21.53 |
| Biote (BTMD) | United States | $0.170B | 5.64 |
| Jushi Holdings (JUSHF) | United States | $0.149B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.114B | 0.00 |
| MacroGenics (MGNX) | United States | $0.112B | 0.00 |
| Jin Medical (ZJYL) | China | $0.111B | 0.00 |
| Fonar (FONR) | United States | $0.099B | 12.78 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.090B | 0.00 |
| Apyx Medical (APYX) | United States | $0.075B | 0.00 |
| Agape ATP (ATPC) | $0.066B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.062B | 0.00 |
| MariMed (MRMD) | United States | $0.060B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.059B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.059B | 0.00 |
| ImmuCell (ICCC) | United States | $0.058B | 33.68 |
| Zynex (ZYXI) | United States | $0.050B | 0.00 |
| Veru (VERU) | United States | $0.048B | 0.00 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| United-Guardian (UG) | United States | $0.039B | 15.02 |
| Senestech (SNES) | United States | $0.024B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.017B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Cellectar Biosciences (CLRB) | United States | $0.016B | 0.00 |
| Sharps Technology (STSS) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |